The abstract is read at the publisher; the summary is JClub's.
Erythropoietin added to therapeutic hypothermia in term or near-term infants with moderate-to-severe neonatal HIE did not significantly reduce death or disability at 2 years (34.1% vs 28.7%).
- Why it matters: Even with therapeutic hypothermia, mortality and long-term morbidity after neonatal hypoxic-ischemic encephalopathy remain substantial, motivating evaluation of adjunct therapies.
- What they did: In a phase 3, multicenter, double-blinded randomized trial in 24 NICUs across Australia, New Zealand, and Singapore, infants received intravenous EPO 1000 IU/kg (five doses over the first week) or placebo alongside hypothermia.
- The result: Among 313 randomized infants, the primary composite outcome showed no significant difference (relative risk 1.19; 95% CI 0.84–1.68; P=.33), and no safety concerns emerged.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.